4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2026)
4D Molecular Therapeutics (FDMT) reported Enterprise Value of -$390.9 million for Q1 2026, down 21.61% year-over-year from -$498.6 million in Q1 2025, and up 2.92% quarter-over-quarter from -$402.7 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Enterprise Value (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has 8 years of Enterprise Value data on file, last reported at -$390.9 million in Q1 2026.
- Enterprise Value for Q1 2026 came in at -$390.9 million, down 21.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$390.9 million (down 21.61% YoY), and the FY2025 annual result was -$402.7 million, up 5.23% from the prior year.
- Enterprise Value rose to -$390.9 million in Q1 2026 per FDMT's latest filing, from -$402.7 million in the prior quarter.
- Over five years, Enterprise Value peaked at -$200.5 million in Q1 2023 and troughed at -$541.9 million in Q2 2024.
- A 5-year average of -$337.9 million and a median of -$310.3 million in 2023 frame the typical range for Enterprise Value.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value tumbled 162.36% in 2024, then surged 45.89% in 2025.
- A 5-year view of Enterprise Value shows it stood at -$213.6 million in 2022, then tumbled by 34.97% to -$288.2 million in 2023, then slumped by 47.41% to -$424.9 million in 2024, then grew by 5.23% to -$402.7 million in 2025, then rose by 2.92% to -$390.9 million in 2026.
- Business Quant data shows FDMT's Enterprise Value at -$390.9 million in Q1 2026, -$402.7 million in Q4 2025, and -$305.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | -32.30 Mn |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -4.14 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -286.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -18.44 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.77 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -7.20 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -7.25 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -584.73 Mn |
| 10 | 4D Molecular Therapeutics | 656.48 Mn | 656.48 Mn | - | -390.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -390.89 Mn |
| Dec 31, 2025 | -402.66 Mn |
| Sep 30, 2025 | -305.06 Mn |
| Jun 30, 2025 | -293.23 Mn |
| Mar 31, 2025 | -321.44 Mn |
| Dec 31, 2024 | -424.88 Mn |
| Sep 30, 2024 | -501.89 Mn |
| Jun 30, 2024 | -541.95 Mn |
| Mar 31, 2024 | -525.91 Mn |
| Dec 31, 2023 | -288.23 Mn |
| Sep 30, 2023 | -319.66 Mn |
| Jun 30, 2023 | -310.34 Mn |
| Mar 31, 2023 | -200.45 Mn |
| Dec 31, 2022 | -213.55 Mn |
| Sep 30, 2022 | -227.72 Mn |
| Jun 30, 2022 | -241.09 Mn |
| Mar 31, 2022 | -236.15 Mn |
| Dec 31, 2021 | -247.78 Mn |
| Sep 30, 2021 | -161.68 Mn |
| Jun 30, 2021 | -243.74 Mn |